Pros
1. The mission - trying to help providers treat cancer patients more effectively + help pharma develop better treatments 2. Reasonable compensation
Cons
1. Current leadership has placed the mission out of reach - or maybe they're not even honestly interested in it 2. Toxic environment - I can't tell you how many times I saw tears from employees, employees speaking about health problems from the stress (especially starting in 2022, it was reasonable before that), abusive behavior from senior leadership based on teams missing imposed, fantasy timelines 3. Almost all the best people gave up on Ontada in late 2021 & 2022, the attrition was brutal. They were replaced by friends of the new CTO, sycophants or (more often than not) just not replaced 4. the new CTO (Sagran Moodley) was either an irresponsible hire from President Susan Schiff, or a deeply cynical hire. I heard some terrible things about him from United Healthcare employees (his previous employer), there was either no due diligence or she just didn't care to find out who he was. He's confirmed everything from the comments I heard - he has a sociopathic disregard for the health & wellbeing of employees (so much for 'iCare' & 'iLead', the supposed values of parent company McKesson) 5. Sagran quickly gave up on any efforts related to cancer care (such as the Mobile app & redesign/re-engineering of the EHR) and made wildly irresponsible promises to rebuild apps aligned to McKesson / distribution with crazy short timelines. Every time reality intervened & deadlines were missed, he publicly shamed & abused his employees. It didn't take long for everyone to see he was trying to make a show for McKesson skip-level execs rather than deliver on the more difficult Ontada vision, probably based on some bonus package offered to bring him onboard (?) 6. Sagran is cutting corners in a way that is at times ethically compromised and could easily result in products that don't deliver value for users or have sustainable tech stacks. It's speed to revenue at all costs, I expect Sagran assumes he'll have cashed out by the time it all comes crashing down 7. Susan Schiff seems completely uninterested in the largest part of her business, the product side. We had to watch her LinkedIn posts to get a sense of what she was thinking, and they were all about some clinical research that more often than not had nothing to do with what we were tasked to do. She apparently got all her information on the product side of the business from Sagran - did that leave her blind to what was going on, or was it for plausible deniability? Is she okay with a collapse in talent because it makes it easier to offshore everything? There have been a ton of layoffs in tech and Ontada is probably hiring due to the attrition (I haven't checked), but just know going in - your job is to help developers in India create mediocre (at best) products under brutal timelines and with constant abuse.
